For instance, reducing inflammation through therapies targeting cytokines like IL-6 and tumor necrosis factor alpha (TNF-α) could improve clinical outcomes and enhance the effectiveness of chemotherapy and immunotherapy in DLBCL patients. Here, TNF is linked to diffuse large B-cell lymphoma.